In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

She also highlighted a few trial design considerations. Isaacs noted the differing lengths of treatment between arms, with patients on the investigational arm continuing trastuzumab deruxtecan ...

emphasizing the importance of well-structured multicenter design in oncology trials. AstraZeneca and Daiichi Sankyo have shared positive data from the Phase III DESTINY-Breast09 clinical trial ...

The novel trial design used ctDNA monitoring at the time of routine ... to address the biologically diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, ...

The novel trial design used ctDNA monitoring at the ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are ...

This includes the relevant patents, clinical data, regulatory approvals, manufacturing expertise, and insight into ADC chemistry and design ... also known as trastuzumab deruxtecan or T-DXd ...

Despite the lack of a study directly comparing trastuzumab deruxtecan and trastuzumab rezetecan ... have a similar type of drug and study design, the same primary endpoint and line of treatment ...

showing both a better objective response rate and disease control rate than trastuzumab deruxtecan, with similar toxicity and less severe interstitial lung disease. This improvement could be due to ...